Seeking Alpha

Savient Pharmaceuticals (SVNT +4.4%) says new data presented at the European League Against...

Savient Pharmaceuticals (SVNT +4.4%) says new data presented at the European League Against Rheumatism congress showed patients with refractory chronic gout also suffering from chronic kidney disease responded to treatment with its drug Krystexxa regardless of its baseline chronic kidney disease stage. The company is seeking approval for Krystexxa in Europe.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs